



BEXSERO


Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)



DID YOU KNOW?

VACCINATION AGAINST MENB* IS NOT PART OF YOUR CHILD'S ROUTINE VACCINATION SCHEDULE

BEXSERO is a vaccine for individuals from 2 months through 25 years of age for the prevention of meningococcal disease caused by the *Neisseria meningitidis* group B bacteria.



* Meningococcal disease caused by *Neisseria meningitidis* group B strains.

**Help protect
them against MenB*
with BEXSERO.**

ABOUT INVASIVE MENINGOCOCCAL DISEASE (IMD)



Meningococcal disease starts quickly and may progress within 24 hours to serious, possibly life-threatening infections.*

* BEXSERO does not treat or reduce the consequences of meningococcal meningitis, including meningitis, sepsis (blood poisoning), and death.



Up to **1 in 10 patients die** (typically within 24 to 48 hours after the onset of symptoms).*

* BEXSERO does not treat or reduce the consequences of meningococcal meningitis, including meningitis, sepsis (blood poisoning), and death.



Of those who recover, **up to 1 in 3 patients experience serious complications**, including hearing loss, neurologic disabilities, and amputations.*

* BEXSERO does not treat or reduce the consequences of meningococcal meningitis, including meningitis, sepsis (blood poisoning), and death.



Because **symptoms begin mildly**, like a cold or flu (e.g., fever, headache, aches and pains in joints and muscles), they can be **difficult to diagnose**.



Between 2013 and 2017, the highest incidence of IMD was in **infants** under 1 year of age. Additionally, MenB[†] accounted for 80% of all IMD cases in infants and children.[‡]


- The incidence of IMD (per 100,000 people) in infants <1 year of age was 3.0; and ranged from 0.1 to 0.7 (per 100,000 people) for the other age groups.

[†] BEXSERO is indicated for individuals 2 months through 25 years of age.



In Canada, invasive meningococcal disease (IMD) is most commonly associated with *Neisseria meningitidis* (meningococcus bacteria) strains A, B, C, W-135, and Y.[‡]

[‡] BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains. Protection against IMD caused by other serogroups has not been studied, therefore, protection against IMD caused by other serogroups should not be assumed.



MenB[§] was the leading cause of IMD in Canada from 2013 through 2017.[¶]

[§] Meningococcal disease caused by *Neisseria meningitidis* group B strains.

[¶] From 2013 to 2017, a total of 548 IMD cases were reported in Canada. Incidence rate was highest in infants less than 1 year of age at 3.0 cases per 100,000 population and ranged from 0.1 to 0.7 per 100,000 population for the other age groups.

VACCINATION AGAINST MENB[§] IS NOT PART OF YOUR CHILD'S ROUTINE VACCINATION SCHEDULE.

HELP PROTECT YOUR CHILD AGAINST MENB[§] WITH BEXSERO.

HOW IS MENINGOCOCCAL DISEASE SPREAD?



The **bacteria** that cause invasive meningococcal disease **may spread through close contact** with other people. Examples include but are not limited to:

- Coughing and sneezing
- Kissing or close physical contact
- Sharing eating utensils and drinking glasses



Some people can carry the *Neisseria meningitidis* bacteria without developing the disease.

- An individual infected with meningococcal bacteria can spread the disease up to 7 days before showing symptoms of meningococcal disease.
- Up to 1 in 10 healthy people are carriers of the infection and may remain a carrier for up to 6 months without any symptoms.

Because preventing the spread of germs—especially among children and adolescents—is nearly impossible, vaccination becomes an important consideration.

* Meningococcal disease caused by *Neisseria meningitidis* group B strains.

**TALK TO YOUR
HEALTHCARE PROVIDER ABOUT
VACCINATION AGAINST
MENB* WITH BEXSERO.**





Help protect her
against MenB*
with BEXSERO.

ABOUT BEXSERO

It's the **first and only** vaccine against MenB* indicated in infants as young as **2 months of age**.†

- BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of meningococcal disease caused by *Neisseria meningitidis* group B bacteria in individuals from 2 months through 25 years of age.

SELECT MENINGOCOCCAL VACCINES AVAILABLE IN CANADA

| Strain coverage | BEXSERO | Quadrivalent conjugate meningococcal vaccines |
|-----------------|---------|---|
| A | | ✓ |
| C | | ✓ |
| Y | | ✓ |
| W-135 | | ✓ |
| B | ✓ | |

Help protect against **MenB*** with BEXSERO. IMD caused by MenB* can cause serious outcomes, such as:

- **Meningitis** (infection of the lining of the brain and spinal cord)
- **Sepsis** (blood poisoning)

Both of these conditions are serious and can be life-threatening.

* Meningococcal disease caused by *Neisseria meningitidis* group B strains.

† Comparative clinical significance unknown.

BEXSERO does not treat or reduce the consequences of IMD caused by MenB*, including meningitis, sepsis, and death.

**VACCINATION AGAINST MENB*
IS NOT PART OF YOUR CHILD'S
ROUTINE VACCINATION SCHEDULE.**

**ASK YOUR HEALTHCARE PROVIDER
IF BEXSERO IS APPROPRIATE
FOR YOUR CHILD.**

BEXSERO DOSING SCHEDULE

The doctor, pharmacist or nurse will inject BEXSERO into the arm or leg muscle, depending on the age of the patient.

RECOMMENDED VACCINATION SCHEDULE:

| Age group at time of first dose | Primary immunization | | Booster dose (0.5 mL) |
|---|---|--------------------------------------|--|
| | Primary doses <i>Each dose is 0.5 mL</i> | Interval between primary doses | |
| Infants (Option 1) 2 through 5 months of age | 2+1 dosing schedule (Option 1) | | 1 dose Required in the 2nd year of life after an interval of ≥6 months from the last injection of the initial course. |
| | 2 | ≥2 months | |
| Infants (Option 2) 2 through 5 months of age | 3+1 dosing schedule (Option 2) | | 1 dose Required in the 2nd year of life after an interval of ≥6 months from the last injection of the initial course. |
| | 3 | ≥1 month | |
| Infants 6 through 11 months of age | 2 | ≥2 months | 1 dose Required in the 2nd year of life, after an interval of ≥2 months from the last dose. |
| Children 12 months through 23 months | 2 | ≥2 months | 1 dose Required after an interval of 12 to 23 months from the second injection. |
| Children, adoles- cents and adults 2 through 25 years of age | 2 | ≥1 month | 1 dose Considered in individuals at continuous risk of exposure to meningococcal disease. |

Vaccination against MenB* is not part of your child’s routine vaccination schedule. Help protect your child against MenB* with BEXSERO.

Please refer to the package insert for complete dosing information.

* Meningococcal disease caused by *Neisseria meningitidis* group B strains.

Date of initial dose: _____ / ____ / ____

GET VACCINATED AGAINST MENB*.

Here's how:

1

Talk to your healthcare provider about vaccinating with BEXSERO.

2

Schedule on appointment for the first dose.

- Bring your child's immunization booklet, if you have it, and the BEXSERO dosing schedule (from this brochure) to each appointment.
- Ask your healthcare professional to write down the date and time of the first dose in the BEXSERO schedule and in the immunization booklet.

3

Make an appointment for the next dose.

- Sign up for dose reminders at **BEXSERO.ca** to ensure that you get all required doses of BEXSERO.

BEXSERO may be covered by your private insurance. Contact your insurance provider and give the drug identification number (DIN) below to find out.

BEXSERO DIN: 02417030.

TALK TO YOUR HEALTHCARE PROVIDER ABOUT MENB* AND BEXSERO.

BEXSERO side effects

Like all vaccines, BEXSERO may cause side effects, although not everybody gets them.

When BEXSERO is given, the very common side effects (affecting >1 in 10 people) your child† may experience at the injection site include pain/tenderness, redness, swelling or hardness of the skin at the injection site.

The following side effects may also occur after receiving this vaccine.

Infants and children (2 months to 10 years of age)

Very common (may affect >1 in 10 people)

- fever ($\geq 38^{\circ}\text{C}$), loss of appetite, tenderness or discomfort at injection site (including severe injection site tenderness resulting in crying when injected limb is moved), skin rash, sleepiness, feeling irritable, unusual crying, vomiting (uncommon after booster), diarrhea, headache and painful joints

Adolescents and adults (≥ 11 years of age)

Very common (may affect >1 in 10 people)

- pain at injection site resulting in inability to perform normal daily activity, painful muscles and joints, nausea, generally feeling unwell and headache

These are not all the possible side effects your child may feel when taking BEXSERO. If any of the noted side effects become serious, or if you notice any side effects not listed, please tell your doctor, pharmacist or nurse immediately.

BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of meningococcal disease caused by *Neisseria meningitidis* group B bacteria in individuals from 2 months through 25 years of age. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal meningitis, including meningitis, sepsis, and death. Ask your healthcare professional if BEXSERO is right for your child. Full product information can be found at <http://gsk.ca/bexsero/en>. To report an adverse event, please call 1-800-387-7374.

* Meningococcal disease caused by *Neisseria meningitidis* group B strains.

* Meningococcal disease caused by *Neisseria meningitidis* group B strains.
† Reported in all age groups 2 months through 25 years of age.



DID YOU KNOW THAT VACCINATION AGAINST MENB* IS NOT PART OF YOUR TEEN'S ROUTINE VACCINATION SCHEDULE?

VISIT [BEXSERO.CA](https://www.bexsero.ca) FOR MORE INFORMATION
AND OTHER HELPFUL RESOURCES.



**BEXSERO DIN:
02417030.**

* Meningococcal disease caused by *Neisseria meningitidis* group B strains.

Trademarks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.



04500
06/21